<< Back
Mar 02, 2017

Tandem Diabetes Care Launches First Ever Remote Software Update for Insulin Pump using a Personal Computer

Software Update Available for all t:slim® Insulin Pumps Purchased Before April 2015

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the release of a software update for t:slim® Insulin Pumps purchased before April 2015. The software update will be available via personal computer using the Tandem Device Updater, a Mac® and PC-compatible tool for the remote deployment of Tandem insulin pump software. This represents the first time an insulin pump manufacturer has provided a software update for customers using their personal computer.

"The innovative, first-of-its-kind Tandem Device Updater represents an important advancement in the way functionality is delivered to insulin pump users, making it possible to provide new pump features to our customers independent of the typical pump insurance replacement cycle," said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "We are working on exciting new software updates to offer our customers as they are approved by the FDA, such as integration with Dexcom's G5 Mobile CGM system and automated insulin delivery algorithms, and today's launch is the first step in this direction."

The software update launched today provides the latest t:slim Insulin Pump software to in-warranty t:slim Pumps purchased before April 2015. The features included in this software release began shipping on new t:slim Pumps in April 2015, and include a variety of product enhancements for convenience and flexibility.

In-warranty customers who purchased their t:slim Pump before April 2015 will receive an email in the next three weeks with their unique Update ID Number and instructions on how to update their pump.

Consistent with past product development efforts, the design of the Tandem Device Updater was driven significantly by direct input from pump users. Following clearance by the U.S. Food and Drug Administration, Tandem conducted additional customer testing to further refine the user experience. Approximately two thirds of the 300 customers who participated in the beta release completed a survey after their download. Survey results reported that the product was easy to use, with more than 90% indicating they would be likely to download future software updates.

To learn more about the Tandem Device Updater, visit www.tandemdiabetes.com/updater.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touchscreen simplicity. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

t:slim, t:flex, and Tandem Diabetes Care are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. All other trademarks are the property of their respective owners.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the Company's ability to offer future software improvements and enhancements to Tandem pumps using the Tandem Device Updater and the Company's ongoing development activities for integration of Dexcom's G5 sensor and automated insulin delivery algorithms. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the Company's products, including the Tandem Device Updater, may be negatively impacted by lack of market acceptance by physicians, payors and people with diabetes; the potential that newer products that compete with the Company's products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company's products, including the Tandem Device Updater, obsolete or less desirable; the potential that the Tandem Device Updater may fail to perform according to its specifications or may not provide people with diabetes with anticipated benefits; and the potential that the Company may not be able to successfully complete the development of some or all of the future software improvements and enhancements to Tandem pumps, or that those software improvements and enhancements may not be approved by the FDA in a timely manner or at all. Other risks and uncertainties are identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer, 714-907-6264
Investor Contact:
Susan Morrison, 858-366-6900 x7005

Source: Tandem Diabetes Care, Inc.

News Provided by Acquire Media